Psychiatry’s prior-authorization burden has a specific shape: the gating of treatment-resistant depression care. For patients who haven’t responded to standard antidepressants, the next clinical options — transcranial magnetic stimulation (TMS) and esketamine (Spravato) — require prior authorization, and the criteria are structured as documented failure of what came before.
The requirement is step therapy by another name: prove the cheaper path didn’t work before the payer will cover the one that might.
The numbers in psychiatry
The step-therapy requirement for TMS and Spravato is not a rare edge case — it is the standard payer policy:
- ≥2 documented antidepressant failures are required by most major payers before TMS or Spravato will be approved. Specific payers set their own definitions of adequate trial duration and dosage.
- Behavioral health carve-outs create a second PA queue: the same patient may need authorization through the medical benefit and the MBHO, running independent processes.
These sit on the baseline every physician carries: 39 authorizations per week, roughly 13 hours lost to them, 93% reporting that PA delays care, and 82% saying PA can lead patients to abandon treatment (AMA 2024). In psychiatry, abandonment carries different consequences than in most specialties. The research linking psychiatric step therapy to higher rates of hospitalization and incarceration reflects what happens when access is delayed for a patient population that is often already destabilized.
Why psychiatry is different
- Documented failure is the criterion. TMS and Spravato are approved for treatment-resistant depression — but “treatment-resistant” has to be assembled into documentation the payer will accept: drug names, dosages, duration, reason for discontinuation. That documentation has to match the payer’s specific definition of adequate trial, which varies.
- The carve-out problem. Behavioral health carve-outs separate the behavioral benefit from the medical benefit administratively. A psychiatrist in a practice that contracts with both may need to authorize the same patient through different organizations with different systems, different timelines, and different criteria.
- Atypical antipsychotics. Beyond TMS and Spravato, psychiatrists routinely face PA on adjunctive atypical antipsychotics and long-acting injectable formulations — each with its own formulary tier and step-therapy requirements.
- The stakes of delay. Treatment-resistant depression is not a condition that waits well. A two-week PA delay for a patient in crisis is categorically different from a two-week delay for a maintenance biologic.
What it costs
The cost in psychiatry is not abstract. Step therapy for psychiatric medications is associated with higher rates of hospitalization and incarceration in the published literature — outcomes that attach, in part, to delayed access to effective treatment. The operational cost is staff hours assembling antidepressant failure histories and navigating two separate authorization queues, at roughly $10.81 per manually processed authorization (CAQH 2023), for a patient population that needs the treatment sooner rather than later.
How to cut the wait
The TMS and Spravato authorization packet is structured clinical history: prior medications, adequate-trial documentation, treatment-resistance criteria. Artificer Health:
- Builds the prior-medication record — drugs tried, dosages, durations, and the reason each was discontinued, in the format each payer’s step-therapy criteria require.
- Routes to the right authorization system — medical benefit or behavioral health carve-out — so the submission lands in the right queue the first time.
- Tracks re-authorizations for ongoing treatment so therapy never lapses for a paperwork reason while the patient is in a course of TMS or continuing Spravato.
For treatment-resistant depression, weeks matter. The goal is to get the authorization resolved in hours, not across the weeks of back-and-forth that a poorly assembled first submission creates.
Further reading: TMS Prior Authorization Guide for OCD: Requirements by Payer (2025–2026) — device requirements, Y-BOCS thresholds, SSRI step therapy, and payer-specific criteria for deep TMS authorization.
Sources: AMA 2024 Prior Authorization Physician Survey (n=1,000); payer medical policies for esketamine (Spravato) and TMS (documented failure of ≥2 antidepressants); published literature on step therapy for psychiatric medications and downstream outcomes; CAQH 2023 Index.